|
Author:
|
Cantelli, Gaia; Orgaz, Jose L.; Rodríguez Hernández, Irene; Karagiannis, Panagiotis; Maiques Carlos, Oscar; Matias-Guiu, Xavier; Nestle, Frank O.; Martí Laborda, Rosa Ma.; Karagiannis, Sophia N.; Sanz Moreno, Victoria
|
|
Notes:
|
Cell migration underlies metastatic dissemination of cancer cells, and fast “amoeboid” migration in the invasive fronts of tumors is controlled by high levels of actomyosin contractility. How amoeboid migration is regulated by extracellular signals and sustained over time by transcriptional changes is not fully understood. Transforming growth factor β (TGF-β) is well known to promote epithelial-to-mesenchymal transition (EMT) and contribute to metastasis, but melanocytes are neural crest derivatives that have undergone EMT during embryonic development. Surprisingly, we find that in melanoma, TGF-β promotes amoeboid features such as cell rounding, membrane blebbing, high levels of contractility, and increased invasion. Using genome-wide transcriptomics, we find that amoeboid melanoma cells are enriched in a TGF-β-driven signature. We observe that downstream of TGF-β, SMAD2 and its adaptor CITED1 control amoeboid behavior by regulating the expression of key genes that activate contractile forces. Moreover, CITED1 is highly upregulated during melanoma progression, and its high expression is associated with poor prognosis. CITED1 is coupled to a contractile-rounded, amoeboid phenotype in a panel of 16 melanoma cell lines, in mouse melanoma xenografts, and in 47 human melanoma patients. Its expression is also enriched in the invasive fronts of lesions. Functionally, we show how the TGF-β-SMAD2-CITED1 axis promotes different steps associated with progression: melanoma detachment from keratinocytes, 2D and 3D migration, attachment to endothelial cells, and in vivo lung metastatic initial colonization and outgrowth. We propose a novel mechanism by which TGF-β-induced transcription sustains actomyosin force in melanoma cells and thereby promotes melanoma progression independently of EMT.
This work was supported by Cancer Research UK C33043/A12065 (V.S.-M. and J.L.O.), Royal Society RG110591 (V.S.-M.). G.C. is funded by the Medical Research Council (C97993H). I.R.H. is funded by Fundacion Alonso Martin Escudero. S.N.K. and P.K. were supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London. R.M.M. was supported by FIS (PI12/00260) and FMTV-3 (201331-31). |
